The company was launched in May 2023, with Flagship making an initial commitment of $50 million to advance Metaphore’s MIMiC platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications. The MIMiC platform is a computationally driven bioplatform designing new therapeutics where function, specificity, and selectivity can be optimized.